<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Viridian Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/viridian-therapeutics-inc</link>
<description>Latest news and press releases for Viridian Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/viridian-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d39078dffbe2df1209d6.webp</url>
<title>Viridian Therapeutics Inc</title>
<link>https://6ix.com/company/viridian-therapeutics-inc</link>
</image>
<item>
<title>Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-positive-topline-results-from-elegrobart-phase-3-reveal1-clinical-trial-in-active-thyroid-eye-disease</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-positive-topline-results-from-elegrobart-phase-3-reveal1-clinical-trial-in-active-thyroid-eye-disease</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>- REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W</description>
</item>
<item>
<title>Bambusa Therapeutics Appoints Todd James Chief Financial Officer</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/bambusa-therapeutics-appoints-todd-james-chief-financial-officer-1</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/bambusa-therapeutics-appoints-todd-james-chief-financial-officer-1</guid>
<pubDate>Thu, 19 Mar 2026 12:30:00 GMT</pubDate>
<description>Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), today announced the appointment of Mr. Todd James as Executive Vice President, Chief Financial Officer (CFO). Mr. James's appointment strengthens Bambusa's financial leadership, stakeholder engagement, and expands its executive team as the Company advances its clinical pipeline and executes its long-term growth strategy.</description>
</item>
<item>
<title>Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-highlights-recent-progress-and-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-highlights-recent-progress-and-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 12:01:00 GMT</pubDate>
<description>WALTHAM, Mass., February 26, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-1</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-1</guid>
<pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing</description>
</item>
<item>
<title>Viridian Therapeutics Prepares for Transformational 2026</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-prepares-transformational-2026-120100614</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-prepares-transformational-2026-120100614</guid>
<pubDate>Tue, 06 Jan 2026 12:01:00 GMT</pubDate>
<description>WALTHAM, Mass., January 06, 2026--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing ...</description>
</item>
<item>
<title>Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-bla-acceptance-and-priority-review-veligrotug</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-bla-acceptance-and-priority-review-veligrotug</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>- PDUFA target action date of June 30, 2026 - - Priority Review designation is granted to applications for drugs that, if approved, would be a significant</description>
</item>
<item>
<title>Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-reports-third-quarter-2025-financial-results-and-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-reports-third-quarter-2025-financial-results-and-highlights</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>- Completed a comprehensive set of financing transactions in October 2025, securing access to up to $889 million of potential capital across equity, royalty,</description>
</item>
<item>
<title>Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-successful-october-submission-biologics-license</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-successful-october-submission-biologics-license</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>- BLA for veligrotug successfully submitted to the U.S. Food and Drug Administration (FDA) in late October following recent consultation with the agency - -</description>
</item>
<item>
<title>Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-pricing-251-million-public-offering-shares-common</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-pricing-251-million-public-offering-shares-common</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing</description>
</item>
<item>
<title>Viridian Therapeutics Announces Proposed Underwritten Public Offering</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-proposed-underwritten-public-offering-2025-10-21</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-proposed-underwritten-public-offering-2025-10-21</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing</description>
</item>
<item>
<title>Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-royalty-financing-dri-healthcare-300-million-2025-10</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-royalty-financing-dri-healthcare-300-million-2025-10</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>- Viridian receives $55 million upfront and potential near-term milestones up to $115 million based on positive VRDN-003 topline data and U.S. veligrotug</description>
</item>
<item>
<title>Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-completion-enrollment-both-reveal-clinical-trials-and</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-completion-enrollment-both-reveal-clinical-trials-and</guid>
<pubDate>Mon, 15 Sep 2025 04:00:00 GMT</pubDate>
<description>- Enrollment complete in VRDN-003’s phase 3 clinical trials in thyroid eye disease (TED), REVEAL-1 and REVEAL-2, with each study exceeding its enrollment</description>
</item>
<item>
<title>Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-highlights-recent-progress-and-reports-second-quarter-2025</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-highlights-recent-progress-and-reports-second-quarter-2025</guid>
<pubDate>Wed, 06 Aug 2025 04:00:00 GMT</pubDate>
<description>- Robust execution with multiple upcoming near-term milestones, including planned Biologics License Application (BLA) submission for veligrotug on track in</description>
</item>
<item>
<title>Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-collaboration-and-license-agreement-kissei</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-collaboration-and-license-agreement-kissei</guid>
<pubDate>Wed, 30 Jul 2025 04:00:00 GMT</pubDate>
<description>- Kissei obtains an exclusive license to develop and commercialize veligrotug and VRDN-003 in Japan - - Viridian to receive an upfront payment of $70 million</description>
</item>
<item>
<title>Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Thu, 03 Jul 2025 04:00:00 GMT</pubDate>
<description>BOULDER, Colo., July 14, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (“the “Company” or “Viridian”), a biopharmaceutical company</description>
</item>
<item>
<title>Viridian Therapeutics to Participate in Upcoming June Investor Conferences</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-participate-upcoming-june-investor-conferences-2025-05-30</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-participate-upcoming-june-investor-conferences-2025-05-30</guid>
<pubDate>Fri, 30 May 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and</description>
</item>
<item>
<title>Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-positive-long-term-durability-data-veligrotug-phase-3</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-announces-positive-long-term-durability-data-veligrotug-phase-3</guid>
<pubDate>Tue, 20 May 2025 04:00:00 GMT</pubDate>
<description>- 70% of patients treated with veligrotug in THRIVE who were proptosis responders at week 15 maintained their response at week 52 - - Veligrotug recently</description>
</item>
<item>
<title>Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-receives-fda-breakthrough-therapy-designation-veligrotug</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-receives-fda-breakthrough-therapy-designation-veligrotug</guid>
<pubDate>Wed, 07 May 2025 04:00:00 GMT</pubDate>
<description>- Breakthrough Therapy Designation request based on veligrotug’s (i) consistent and robust improvement and resolution of diplopia in chronic TED, and (ii)</description>
</item>
<item>
<title>Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-highlights-recent-progress-and-reports-first-quarter-2025</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-highlights-recent-progress-and-reports-first-quarter-2025</guid>
<pubDate>Tue, 06 May 2025 04:00:00 GMT</pubDate>
<description>- Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commercial</description>
</item>
<item>
<title>Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors</title>
<link>https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-appoints-jeff-ajer-its-board-directors-2025-04-07</link>
<guid isPermaLink="true">https://6ix.com/company/viridian-therapeutics-inc/news/viridian-therapeutics-appoints-jeff-ajer-its-board-directors-2025-04-07</guid>
<pubDate>Mon, 07 Apr 2025 04:00:00 GMT</pubDate>
<description>- Mr. Ajer was most recently Chief Commercial Officer at BioMarin - WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a</description>
</item>
</channel>
</rss>